Sai Life Sciences Receives Income Tax Order Worth INR 4.53 Crore for TDS Non-Deduction
Sai Life Sciences Limited received an income tax order dated 18th March, 2026, from the Deputy Commissioner of Income Tax (International Taxation) Hyderabad under Section 201(1) for non-deduction of TDS on non-resident payments during assessment year 2020-21. The order demands INR 2,54,39,944 in tax and INR 1,99,17,238 in interest, totaling INR 4,53,57,182, plus potential penalties. The company plans to file an appeal and expects a favorable outcome, stating it does not anticipate material financial impact from this order.
*this image is generated using AI for illustrative purposes only.
Sai Life Sciences Limited has informed stock exchanges about receiving an income tax order related to non-deduction of Tax Deducted at Source (TDS) on payments made to non-residents. The pharmaceutical company disclosed this development under Regulation 30 of SEBI Listing Regulations on 21st March, 2026.
Income Tax Order Details
The Deputy Commissioner of Income Tax (International Taxation) Hyderabad passed an order dated 18th March, 2026, under Section 201(1) of the Income Tax Act, 1961. The company received this order on 20th March, 2026, at 12:16 PM. The order addresses alleged violations concerning non-deduction of TDS on payments made to non-residents for assessment year 2020-21.
Financial Implications
The income tax order specifies significant financial demands against the company:
| Component: | Amount (INR) |
|---|---|
| Tax Demand: | 2,54,39,944 |
| Interest: | 1,99,17,238 |
| Penalty: | As may be assessed and levied by the officer |
| Total Quantified Demand: | 4,53,57,182 |
The total quantified demand amounts to INR 4,53,57,182, with additional penalties that may be assessed separately by the income tax officer.
Company's Response and Strategy
Sai Life Sciences has outlined its approach to address this income tax order. The company plans to file an appeal against the order and expressed confidence in achieving a favorable outcome at the appellate level. Based on the company's assessment, it does not reasonably expect the order to have any material financial impact on its operations.
Regulatory Compliance
The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Circular on Industry Standards Note dated 25th February, 2025. The company provided comprehensive details as required under Schedule III of the Listing Regulations, ensuring transparency with stakeholders regarding this regulatory development.
Assessment Year Context
The income tax order specifically relates to assessment year 2020-21, indicating that the alleged TDS non-deduction issues pertain to transactions conducted during that financial period. The order focuses on payments made to non-resident entities, which typically require TDS deduction under Indian income tax provisions for international transactions.
Historical Stock Returns for Sai Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.73% | -5.18% | -3.84% | +8.21% | +26.85% | +25.54% |
How might this TDS dispute affect Sai Life Sciences' future international business partnerships and payment structures with non-resident entities?
What potential impact could similar TDS scrutiny have on other pharmaceutical companies with significant cross-border transactions?
Will this income tax order prompt Sai Life Sciences to revise its tax compliance procedures and increase provisions for international transaction disputes?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
